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Abstract 
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their 
impact in cancer remains largely unknown. Here, we extensively screened for p53 
aggregation phenotypes in tumour biopsies and identified nuclear inclusion bodies (nIBs) of 
transcriptionally inactive mutant or wild-type p53 as the most frequent aggregation-like phenotype 
across six different cancer types. p53-positive nIBs co-stained with nuclear aggregation markers and 
shared molecular hallmarks of nIBs commonly found in neurodegenerative disorders. In cell culture, 
tumour-associated stress was a strong inducer of p53 aggregation and nuclear inclusion body 
formation. This was most prominent for mutant p53, but could also be observed in wild-type p53 
cell lines for which nIB formation correlated to the loss of p53s transcriptional activity. Importantly, 
protein aggregation also fueled the dysregulation of the proteostasis network in the tumour cell by 
inducing a hyper-activated, oncogenic heat-shock response to which tumours are commonly 
addicted, and by overloading the proteasomal degradation system, an observation that was most 
pronounced for structurally destabilized mutant p53. Patients exhibiting tumours with p53-
positive nIBs suffered from a poor clinical outcome similar to loss-of-p53-expression, and tumour 
biopsies displayed a differential proteostatic expression profile associated to p53-nIBs. p53-positive 
nIBs therefore highlight a malignant state of the tumour that results from the interplay between (i) 
the functional inactivation of p53 through mutation and/or aggregation and (ii) microenvironmental 
stress, a combination that catalyses proteostatic dysregulation. This study highlights 
several unexpected clinical, biological and therapeutically unexplored parallels between cancer and 
neurodegeneration. 
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Introduction  
The cellular protein quality control (PQC) machinery of chaperones and proteases ensures 
protein homeostasis or ‘proteostasis’ (1-3). Due to ageing, mutation or  
(patho-)physiological insults (4), the processing of misfolded proteins becomes less efficient, which 
can lead to protein accumulation and aggregation, and vice versa (1-3). Abnormal protein 
aggregation causes well-known misfolding diseases, including neurodegenerative and amyloidogenic 
disorders (1-3), which typically accumulate disease-specific proteins in inclusion bodies or 
extracellular deposits (1-3). In rare familial cases, germ line mutations increase aggregation 
propensity of disease-specific proteins, the chronic expression of which is believed to initiate a 
vicious cycle of proteostatic dysregulation and aggregation. In the more common sporadic 
conformational diseases, an age-associated erosion of PQC is more likely to cause wild-type protein 
aggregation.  
Tumour suppressor p53 is the most commonly mutated gene in cancer (5). Most mutations 
occur in the DNA binding domain and can be categorized according to their conformational effect: 
while ‘contact’ mutations alter DNA-binding properties without disturbing the overall folding, 
‘structural’ mutations disrupt the native fold (6, 7). Inactivity of p53 commonly correlates with its 
aberrant accumulation in cancer cells (5, 8), which was initially explained by an impeded human 
Double Minute-2 (MDM2) response that mediates p53 degradation (9). Recently, we and others 
showed that aggregation can also contribute to p53 inactivation, accumulation and gain-of-function 
activities (10-18). Importantly, although mutation often increases the aggregation propensity of p53 
by destabilizing its structure, p53-wild type (p53-WT) is in itself already thermodynamically labile 
(Tmelt 42°C) (10, 15, 16). As ageing favours both mutation and proteostatic decline, the aggregation of 
both mutant and p53-WT might be a common and possibly physiology-modifying event. The 
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accumulation of p53 aggregates has been previously reported by us and others in tumour lines 
transiently overexpressing mutant p53 or in sparse human tumours (13, 14, 17, 19). 
Here, we present a study agglomerating 370 tumour biopsies investigating the presence of 
p53 aggregates in cancer. We find that a large fraction of mutant and p53-WT-positive tumours 
contain nuclear inclusion bodies of inactive p53 which co-localize with known markers for 
aggregates in neurodegeneration. The presence of aggregated p53 in cell lines and nIBs in tumours 
associate with a distinctive proteostatic profile and patient survival. 
Methods  
Cell lines 
Cells were grown in standard conditions (DMEM/10%FCS; Life technologies). Stress insults included 
hypoxia (0.5% Oxygen), proteostatic stress (0.5 µM MG132, M7449, Sigma-Aldrich), hypoglycemia 
(DMEM without glucose) and oxidative stress (100µM NiCl2). 
SDS-Gradient BN-PAGE analysis 
Cells were lysed in 150mM NaCl, 50mM TrisHCl pH8, 1% IGEPAL(NP40), 1x Complete inhibitor 
(Roche), 1U/µl Universal Nuclease (Pierce) followed by incubation with SDS as indicated. Blue-
Native PAGE analysis was performed as described (17). 
Clinical samples 
Stage II/III colon cancer samples (n=163) were collected by the Department of Abdominal Surgery 
(2004-2006; UZLeuven, Belgium; project #S53472) and Glioblastoma (GBM) samples (n=58, only 
IDH1/2WT) by the Center for Molecular Oncologic pathology (2007-2013; Dana-Farber Cancer 
Institute, Boston, MA, USA; IRB protocol 10-417). Patients were monitored for tumor recurrence and 
overall survival (median follow-up: 50.2 months for colon cancer and 17 months for GBM).  
Antibodies  
Anti-p53 DO-1 and FL393, HSC70, HSP90, HSPA6, DNAJB1 and Sigma Receptor (Santa Cruz 
Biotechnology); PML, Nucleolin, SQSTM1, HDAC6, BAG2 and HSF1 (Abcam); HSP70 (Cell signaling 
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technology); A11(AHB0052), Alexa®-labeled secondary antibodies and DAPI (Life technologies). 
Proximity ligation was performed using Duolink® (Olink) according to manufacturer’s instructions.  
Statistical analysis 
Statistical analyses were performed in R-studio (v0.97.551) using R (v3.0.1) or GraphPad Prism 6.0. 
Kaplan–Meier estimates were used to create survival curves. The Cox Proportional Hazard Model 
and the Score logrank test were used to determine statistical significance. Pairwise comparisons 
were performed using likelihood ratio tests with Bonferroni corrections. Non-parametric Kruskal-
Wallis statistics with Bonferroni correction were used for pairwise comparisons of high content data. 
 
See supplementary information for additional methods. 
Results  
 
Nuclear inclusion bodies of p53 
Aggregation-related diseases are typically characterized by the abnormal accumulation and 
aggregation of disease-specific proteins (1, 3), often observed as intracellular inclusions and/or 
extracellular deposits (2).  To search for p53 aggregation phenotypes, we used immunofluorescent 
(IF) staining with sufficient sensitivity to quantify overall expression levels but also detect 
subcellular inhomogeneities (e.g. inclusion bodies) and aberrant subcellular localisation.  
Staining of a cohort of colon cancer samples (n=163) revealed various subcellular p53 
phenotypes: 71% of the p53-positive tumours contained p53-positive ‘puncta’ within the diffuse p53 
staining pattern of the nucleus in a subset of tumour cells (“p53-postive nuclear inclusion bodies” or 
p53-nIBs), while the remainder presented homogeneous, diffuse nuclear p53 staining throughout the 
tumour (Table 1, Figure 1A,B, Figure S1A-H). The occurrence of p53-nIBs often associated with 
cytosolic staining of lower intensity at a similar frequency (Table1). Occasionally, we observed 
cytoplasmic p53 staining without the presence of nIBs, and pure cytoplasmic IBs were only observed 
once (Figure 1C,D). Using these observations, we defined 5 subcategories: tissue without p53 
expression (NULL); with diffuse, well-dispersed nuclear p53 (SOLUB); with p53-nIBs in >50% 
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(NUCINC50) or 1-5% (NUCINC5) of tumour cells; and with diffuse p53 in nucleus and cytoplasm 
(CYTO). Markedly, this classification could not be made reliably using DAB/HRP staining (Fig.S1I-L), 
explaining why this had not been described earlier. 
Also in biopsies from Glioblastoma (GBM), colon cancer, ovarian cancer, endometrial cancer, 
melanoma and Barrett’s esophagus, we observed p53-nIBs at a tumour-type-specific frequency in 
samples originating from all contributing institutes using both mono- and polyclonal antibodies 
(Table 1, Figure 1E, Figure S1). p53-nIBs therefore constitute a bona fide and widespread, but so-far 
uncharacterized phenotype. Also in lymph nodes containing metastatic colon cancer cells, the p53 
phenotype of the primary tumour was generally maintained (TableS1). 
Biopsies containing p53-nIBs were subsequently co-stained with amyloid dyes (i.e. 
luminescent conjugated oligothiophenes, LCOs) (20) or the conformational-specific antibody A11, 
which recognizes oligomeric aggregates (21). While we did not observe specific LCO staining –
suggesting p53 did not generate textbook amyloids in vivo–, using proximity-ligation, p53/p53-nIBs 
and A11 did co-localize in ovarian tumours (Figure S2), confirming previous findings (14) and 
showing that p53 was primarily present as oligomeric aggregates. The A11-staining was however 
insufficiently reliable and robust for routine screening, forcing us to use p53-nIB detection as 
readout. 
 
nIBs contain transcriptionally inactive mutant or wild-type p53 
  Following p53 genotyping, we observed that, although favoured by p53 mutation, 
homogeneous and nIB phenotypes were present in both p53-WT and mutant tumours (Figure 1F,G, 
Table S3). In the p53-positive samples, p53 transcriptional activity (as measured by MDM2 mRNA 
levels) was also significantly higher in samples containing SOLUB-WT as compared to NUCINC50-WT 
(Figure 1H), while no difference was found between NUCINC50-WT and the p53-NULL group, 
showing a severe impairment of p53 activity when present in nIBs. Expression levels of p21 and BAX 
were highly variable (Figure S2D,E) suggesting p53-independent mechanisms (22-24). TP53 mRNA 
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levels were lower in the NULL samples than in the p53 positive samples (Figure 1I), suggesting 
genetic aberrations. 
 
Mutant p53 accumulates in the nucleus as soluble oligomeric aggregates  
Next, we phenotyped 22 tumour cell lines that endogenously express wild-type, contact or 
structurally-destabilized mutant p53 (Table2). By analysing thousands of single cells under baseline 
conditions using immunofluorescent high-content imaging, p53 was primarily observed in a diffuse 
pattern in the nucleus, as commonly observed (25), from which only 5.1±3.1% of cells showed a 
small amount of nIBs (<2 nIBs/cell). We also determined p53’s folding status by 
immunoprecipitation (IP) using p53-specific conformational antibodies (i.e. pAb1620 for native and 
pAb240 for misfolded p53) (26): while p53-WT and contact mutants largely adopted the 
native/pAb1620-positive conformation, structural mutants predominantly adopted the 
misfolded/pAb240-positive conformation (Table2, Figure S3A). 
Given the overall absence of nIBs in standard cell culture conditions (compared to biopsies) 
and the A11-positivity of p53 in biopsies, p53 was expected to form small oligomeric aggregates, 
similar to neurodegenerative diseases where the presence of soluble oligomeric aggregate 
precursors is often indicative for pathological activity (1, 27). Previously, we optimized a blue native 
(BN) PAGE method that discriminates between native tetrameric p53 and aggregated/oligomeric 
forms, which are recognized by a continuous high-molecular weight smear (17). This procedure was 
further adapted to titrate the stability of the aggregates by applying increasing concentrations of SDS, 
a protein-denaturing detergent. Here, p53-WT displayed little resistance to SDS and consisted mainly 
of native tetrameric p53, which readily disassembled into monomers (Figure 2A, Figure S3B). In all 
mutant tumour lines, we observed high molecular weight smears. Whereas for the contact mutant, 
this smear was entirely resolved above 0.2% SDS, this smear persisted until 0.6% SDS for 
structural/pAb240-positive mutants (Figure 2A, Figure S3C). Moreover, the gradual disappearance of 
this high-molecular weight smear correlated with the appearance of SDS-stable octamers and 
tetramers along with monomeric p53 (Figure S3D). In comparison, p53-WT tetramers already 
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disassembled into monomers below 0.2% SDS (Figure 2A, Figure S3B-D), suggesting that tetramers 
emerging from these high-molecular weight smears are distinct from native p53 tetramers and 
stabilised by non-native interactions.    
Aggregated proteins are usually also more resistant to proteolytic cleavage while misfolded 
proteins are generally more sensitive (28, 29). A dose-response of Proteinase K (ProtK) was 
therefore applied to cell extracts (Figure 2B), showing that p53-WT was more resistant to proteolytic 
degradation at low ProtK concentrations (due to its folded structure), while mutant p53 was readily 
cleaved, demonstrating its misfolded nature. However, proteolytic fragments of mutant p53 were 
also more resistant to higher ProtK concentrations and persisted at concentrations where p53-WT 
was already completely digested, confirming not only the misfolded but also aggregated nature of 
p53.  
Finally, while the majority of p53 was present in the soluble fraction, we also identified a 
small (<5%) insoluble p53 fraction using an SDS-based extraction protocol, adopted from procedures 
to extract Amyloidβ-plaques from Alzheimer brain tissue (30, 31). This showed that cell lines 
containing pAb240-positive mutants consistently had more insoluble p53 that resisted higher SDS 
concentrations (up to 0.6%), compared to p53-WT or contact mutants (<0.1%, Figure 2C). This 
demonstrates that misfolded p53 not only forms more stable soluble aggregates, but also more stable 
insoluble aggregates. Proteolytic cleavage analysis also showed that insoluble p53 aggregates were 
more resistant to ProtK than the soluble aggregates, even though they shared similar digestion 
patterns (Figure 2B). This confirms the aggregated nature of insoluble p53 and suggests that they 
result from the maturation and stabilization of soluble aggregates. Even though amyloid-like p53 
structures had been reported before in only a few tumours by ThT binding, Congo Red birefringence 
and amyloid-specific antibodies (10, 18, 32) the current study on a larger panel of tumour cell lines 
and biopsies suggests that nuclear p53 aggregates are generally not maturing into ordered amyloid 
fibrils (17).  
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Aggregated p53 assembles into nIBs by tumour-associated stress 
The appearance of p53 aggregates in patient biopsies as nIBs versus oligomeric aggregates in 
cell lines is highly reminiscent of findings made in pathologies with a more established connection to 
protein aggregation. Several reports describe diffuse staining patterns of Huntingtin, the protein 
causing Huntington’s Disease, under ideal cell culture conditions and demonstrated that a simple 
proteostatic insult e.g. exposure to proteasomal inhibitors (e.g. MG132), resulted in the immediate 
formation of inclusion bodies, similar to observations in patients (33, 34). Here, exposure to MG132 
also resulted in the formation of p53-nIBs in a set of pAb240-positive lines (Fig.3A). In addition, 
29±6% of cells from the pAb240-positive cell lines had >5 inclusions per cell upon MG132-exposure, 
as opposed to 5.1±3.1% which only showed >2 inclusions/cell under baseline conditions, while cell 
lines containing p53-WT only showed minimal induction of nIBs upon MG132-exposure.  
Exposure to additional tumour-related, micro-environmental stress, including hypoxia, 
hypoglycemia, oxidative and/or proteostatic stress, confirmed that cell lines containing mutant p53 
were readily inclined to form nIBs (Figure 3B). Interestingly, exposure to a combination of stress 
conditions also resulted in the formation of p53-nIBs and aggregates in p53-WT cell lines (Figure 3C-
E, Figure S4A)(17). Finally, while MG132-treatment resulted in minimal changes in the overall p53 
levels, we observed a shift from the soluble to the insoluble fraction (Figure 3F), comparable to 
aggregating proteins in neurodegeneration (35). The insoluble p53 fraction was also more SDS-
resistant for aggregating p53 mutants, even though we also observed a small, but detectable 
insoluble fraction in p53-WT and contact mutants (Figure 3F).  
To analyse the correlation of p53’s transcriptional activity with its presence in nIBs, we used 
HCT116p53WT cells where p53 becomes transcriptionally activated upon exposure to cisplatin. In 
baseline conditions, exposure to cisplatin resulted in a significant induction of p53 responsive genes 
(p21, MDM2, PUMA), strikingly without the formation of p53-nIBs (Figure 3G). However, when 
exposed to a combination of cisplatin and cellular stress (i.e. MG132 and/or hypoxia), the p53 
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response was dampened proportionally to the amount of p53-nIBs (Figure 3G), suggesting that the 
observed nIBs are primarily proteostatic sinks of non-functional protein. 
Overall, cellular stress can inactivate p53 through aggregation and induce p53-nIBs, a 
phenotype that is readily achieved for structurally-destabilized mutants, but can also be observed for 
p53-WT or contact mutants. The impact of proteostatic stress on nIB formation in cell lines might 
also explain the observed offset between aggregation and inclusion body formation in this and an 
earlier study (17).  
 
p53-nIBs are PML and Sigma-1 Receptor positive 
Various known nIB markers were analyzed, of which the nuclear-body marker Promyelocytic 
Leukemia (PML; Figure 4A-E) and Sigma-1 Receptor (SigmaR; Figure 4F) co-localized with p53-nIBs, 
while the nucleolar marker Nucleolin primarily did not (Figure S4B)(36). SigmaR was recently 
identified as a marker for neurodegenerative nIBs (37), suggesting the presence of molecular 
parallels between cancer and neurodegeneration. PML has been detected in nIBs containing poly-
glutamine proteins in neurodegeneration, but has also been connected to p53. Because PML-nIBs 
have been linked to both the activation of p53-WT and to gain-of-function by mutant p53 (38, 39), we 
further analysed p53’s transcriptional functionality in baseline and upon cisplatin or MG132 
treatment (Figure S4C,D). In contrast to the p53-WT cell lines, none of the mutant p53 proteins could 
induce MDM2. Immunoprecipitation (IP) with the conformational antibodies (see above) revealed 
that exposure to MG132 resulted in a loss of well-folded p53 whereas the misfolded conformation 
was maintained (Figure 4G). Finally, double staining of p53 with PML or SigmaR confirmed that these 
markers also co-localized with p53-nIBs in biopsies (Figure 4H-S). 
Overall, proteostatic stress can lead to transcriptionally-dead, misfolded, aggregated p53, 
which can be assembled in PML/SigmaR-positive nIBs upon micro-environmental stress. In addition 
from being p53 activation sites (38, 40-42), these bodies also seem to function as nuclear 
aggreosomes, as previously described for aggregating GFP mutants (43).  
Aggregated p53 dysregulates cellular proteostasis 
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Next, the proteostatic consequences of p53 aggregation in tumour cells were investigated by 
genetically deleting p53 (Figure 5A, Figure S5A,S6). In a mixture of knockout and unmodified cells 
that could be discriminated by immunostaining for p53, we simultaneously measured the protein 
levels of important proteostatic markers, including heat shock transcription factor 1 (HSF1), several 
other constitutive and inducible (co-)chaperones, (HSP70, HSC70, HSP90, HSPA6, DNAJB1 and 
BAG2), and autophagy/aggreosome formation factors (SQSTM1, HDAC6). By analyzing the cells in 
short term, we also determined the dependency/addiction of the cells to aggregated p53, such as 
Detroit562, which could not survive long-term without p53 (Figure S5B).  
Analysis upon removal of aggregated p53 in Detroit562, CHL1, HACAT and HCC827 showed a 
reduction of HSF1 protein levels of ∼20%, while remaining largely unaltered in lines containing p53-
WT or contact mutant (Figure5B, S5C-F). A similar reduction was observed for HSP90 (Figure 5C, 
S5C-F), which significantly correlated to HSF1, but also to HSC70, DNAJB1 and HSPA6 (Figure 5C,D, 
S5C-F). The inducible chaperone HSP70 and co-chaperone BAG2 did not correlate with p53 
aggregation status even though an overall reduction was observed of HSP70 species upon deletion of 
p53 (Figure 5D,E, S5C-F). Finally, HDAC6 and SQSMT1 seemed mutually exclusive and only followed 
the HSF1 pattern occasionally in cell lines containing aggregated p53. This argues that p53 
aggregates enhance HSF1 expression and a subset of its constitutive/oncogenic downstream targets 
(44). Overall, this demonstrates that aggregated p53 contributes to the hyper-activated proteostatic 
response, using a mode-of-action that is distinct from non-aggregated p53.  
It has also been suggested that protein aggregates impair proteasomal degradation by 
overburdening the cellular proteostasis network (45). This was demonstrated by the accumulation of 
unstable fluorescent reporters consisting of GFP fused to destabilizing degrons upon coexpression 
with aggregation-prone (mutant) proteins but not with wild-type/nonaggregating variants (45, 46). 
To probe the effect of p53 aggregation on the ubiquitin-proteasome system (UPS), we overexpressed 
mCherry-fused p53 variants in a HEK293 cell line stably expressing the UbG76V-GFP protein, which 
gets degraded by the UPS in baseline conditions, but accumulates in case of excessive proteasomal 
burden (45, 47). UbG76V-GFP strongly accumulated when cells expressed the structurally-destabilized 
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p53R175H-mCherry above a threshold level, indicating concentration dependent inhibition of 
proteasomal degradation. This was not observed when cells expressed p53-WT-mCherry, and only at 
very high expression levels of the contact mutant p53R273H-mCherry (Fig5G). This observation is 
highly reminiscent of the overexpression of polyglutamine expanded aggregation-prone proteins 
(45), further strengthening the parallels between cancer and neurodegeneration. 
 
Tumours containing p53-nIBs show a differential proteostatic expression profile. 
Also in patients, tumours are known to have an activated chaperone system, partially 
explained by elevated HSF1 (44, 48). Targeted transcriptional analysis, based on a pan-cancer 
microarray analysis from which the most important proteostatic components were extracted 
(TableS4), of colon cancer biopsies identified a combination of proteostatic components, including 
HSP27, HSP90, HSC70, HSPA5, HSPA9, PSMB7, PSMD10 and p62/SQSTM1, that was sufficient to 
differentiate between tumours with (NUCINC50) and without p53-nIBs (SOLUB and NUCINC5) 
(Figure 6A,B), but not with NULL tumours. This corroborates our in vitro findings, and suggests that 
similar mechanisms are also at play in the patient. It is in addition also suggestive for the presence of 
other aggregating proteins with similar effects.  
 
p53-nIBs associate with decreased disease-free and overall survival  
Finally, we correlated the p53-nIB status with clinical follow-up in two distinct cohorts 
(Tables S5,S6). Using the p53-defined subgroups, we observed that colon cancer patients bearing 
tumours with p53-nIBs (NUCINC50) or without p53 expression (NULL) showed a significantly worse 
clinical outcome compared to patients with tumours containing soluble (SOLUB) or minimally 
included (NUCINC5) p53 (Figure 6C,D, TableS2). Due to its small size, the CYTO-group was analyzed 
separately but showed a comparable trend as the NUCINC50-group (Figure S7A,B). Similarly, for 
GBM, a significant correlation of disease-free and overall survival with p53-nIB status was observed 
(Figure 6E,F). We did not find a correlation between p53 protein levels and nIB formation 
(MCC=0.04), corroborating previous results that p53 expression levels per se are an inadequate 
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marker for disease outcome (8). In addition, survival analysis using p53 genotype data alone did not 
reveal a correlation with clinical outcome for neither colon cancer nor GBM, in line with previous 
studies (8), while subgrouping according to p53-nIB status in the same subset did result in patient 
stratification (Figure 6G,H, Figure S7C,D). This suggests that the p53-nIB status integrates the various 
aspects of p53 inactivation better than p53 genotype per se. Given the high median age of cancer 
patients, age-related proteostatic dysregulation could have a more profound impact on p53 
inactivation than initially expected – echoing the observation that sporadic age-related 
neurodegenerative diseases frequently involve the aggregation of wild-type proteins as well. 
Discussion 
 
We and others previously showed that p53 can aggregate in cancer (13, 14, 17), but 
compared to well-known aggregation-associated disorders such as Alzheimer’s disease (AD), the 
clinical relevance of p53 aggregation remains unclear. This study reports the first and largest screen 
for p53 aggregation phenotypes in 370 biopsies across 6 different primary and metastatic cancer 
types by fluorescence immunohistochemistry. We found that the most prevalent p53 aggregation 
phenotype is the accumulation of p53-positive nuclear inclusion bodies (nIBs) of inactive wild-type 
(WT) or mutant p53, a phenotype reminiscent of neurodegenerative disorders. In hindsight, this 
finding is not in contradiction with previous studies reporting p53 aggregates in cytoplasmic 
inclusions (17): while a purely cytoplasmic localization of p53 remains rare, nuclear aggregation of 
p53 was commonly accompanied by ‘cytoplasmic spill-over’, suggesting an interplay between 
nucleus and cytoplasm for PQC (49). 
Features of p53-nIBs included co-localisation with the ‘oligomeric aggregate’-specific 
antibody A11, but also to PML and SigmaR, all markers for (nuclear) protein aggregation in various 
neurological disorders (49), but also nuclear aggregation of GFP mutants (43). p53-nIBs primarily 
did not co-localize to the nucleolus, as opposed to previous observations (50), which points to 
lineage and context dependent mechanisms (51). While favoured by p53 mutation, p53-WT was also 
observed in nIBs. Functionally, p53-nIBs correlated to a loss-of-function phenotype as MDM2 
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expression was repressed in both p53-WT cell lines and in tumours containing nIBs of p53-WT to the 
same extent as p53-null tumours. P53-nIBs are therefore a hallmark of p53 protein inactivation 
through aggregation. Interestingly, nuclear amyloidogenic protein bodies have recently been 
described as a temporary storage mechanism of proteins in neurons to cope with stress (52). It 
remains unknown whether similar mechanisms are at play in cancer. 
Nuclear-IBs containing either wild-type or mutant p53 is also in accordance with the 
pathophysiology of established aggregation diseases, where aggregation can be induced by both 
mutation (e.g. rare cases of familial AD) or physiological stress associated to ageing (1). Indeed, the 
majority of cases of sporadic AD are associated to wild-type protein aggregation (2). The apparent 
genotypic indifference of p53 aggregation in human tumours could therefore be instigated by similar 
mechanisms. First, as cancer is a disease resulting from the accumulation of genetic lesions, most 
commonly to p53, the contribution of mutations to protein aggregation should be more common in 
cancer than in neurodegeneration. This is indeed the case, as overall more than half of p53 nIB-
positive tumours express mutant p53. Second, during tumour formation and progression, cells are 
exposed to severe stress conditions such as hypoxia, oxidative and proteostatic stress and 
hypoglycemia (53), which, along with physiological ageing, might explain the aggregation of p53-WT 
in the remaining nIB-positive tumours.      
We investigated this hypothesis by analysing p53 aggregation in cell lines under normal and 
tumour-associated stress conditions. Under normal growth conditions, structurally destabilised p53 
mutants readily formed SDS and proteinase-K resistant aggregates, while p53-WT did not aggregate. 
Tumour-associated stress, on the other hand, enhanced mutant p53 aggregation, but also induced 
p53-WT aggregation and led to the formation of p53-nIBs of both genotypes in association with the 
same markers. This confirms the presence of nuclear p53 aggregates and demonstrates that both 
mutation and environmental stress can be drivers of the aggregation process. It also recapitulates 
the distinction between protein aggregation and inclusion body formation of misfolded proteins, 
another common finding in aggregation-associated diseases. While protein misfolding/aggregation is 
primarily determined by the intrinsic properties of the protein (i.e. mutants having a higher 
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propensity to aggregate), inclusion body formation is a cellular response to proteostatic stress (and 
can occur both in the case of stress-induced wild-type and mutant aggregation). 
Our results also demonstrate that the accumulation of aggregating p53 is not neutral: By 
removing or overexpressing p53, we showed that aggregated p53 modifies the proteostatic network 
of cancer cells. Expression analysis of HSF1 and other proteostatic components showed that p53 
aggregation alone could already account for more than 20% of the cancer-related heat shock 
response, in addition to hampering basal proteasomal degradation. Interestingly, increased HSF1 
activation, which is also observed upon protein aggregation in neurodegeneration (54), plays a major 
role during oncogenesis where cancer cells become ‘addicted’ to increased levels of chaperones, in 
part explained by an over-activation of HSF1 (48, 55, 56). An increase in protein synthesis has been 
suggested as a ‘malignant’ heat shock driver mechanism in cancer (57). Our findings demonstrate 
that p53 aggregation also contributes significantly to this process, but also suggests that the 
aggregation of other, yet-to-be-identified proteins may contribute to HSF1 dysregulation. 
How does p53 aggregation affect the clinical outcome of patients? This needs to be addressed 
by large and carefully designed clinical studies. This first exploratory analysis suggests that grouping 
tumours into nIB-positive versus nIB-negative groups provided stratification with a worse outcome 
for patients bearing nIB-positive tumours, as opposed to a classification by genotype alone. 
Accordingly, patient biopsies containing nIBs also exhibited a shift in the proteostatic network, 
further showing that nIBs highlight proteostatically altered, malignant tumour cells. Such tumours 
could possibly benefit the most from recently described therapeutics that clear mutant p53 from the 
cancer cell (19, 58). Other p53-targeted strategies (59) that aim at activating p53 could also benefit 
from these observations to identify eligible patients. 
Overall, p53-nIBs should be considered as a hallmark for enhanced malignancy, which results 
from the interplay of p53 inactivation, mutation, accumulation, aggregation and tumour-associated 
stress. Beyond the large difference in disease etiology these findings also suggest unexpected 
parallels between cancer and neurodegeneration at the level of proteostatic regulation of cells, and 
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strategies explored for the treatment of amyloid-associated diseases might therefore be equally 
beneficial for the treatment of cancer.  
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Figure legends 
FIGURE 1. STAINING OF CANCER BIOPSIES REVEALS THE PRESENCE P53 NUCLEAR INCLUSION 
BODIES A-D, p53 immunofluorescence staining of colon cancer biopsies. A-D: overlay of confocal 
images stained for p53 (red) and nuclear DAPI staining (blue); E, Quantification of the number of 
tumours that are p53 positive and/or containing p53 inclusions in various tumour types, as 
indicated. F,G, Bar chart distribution of the inclusion body phenotype in p53 WT or mutant (MUT) 
populations of colon cancer (F) and GBM (G). H,I, For the transcriptional analysis, patient samples 
were divided in four subgroups: NUCINC50-WT (p53-WT-nIBs with >50% of tumour cells containing 
p53-nIBs), MUT (mutant p53 with nIB or diffuse p53 staining), NULL (without p53 expression) and 
SOLUB-WT (diffuse, p53-WT), in which MDM2 (H) or p53 (I) mRNA levels were measured using the 
n-string method in extracted RNA from 86 colon tumour biopsies. * indicates statistical significance. 
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FIGURE 2. BIOCHEMICAL ANALYSIS OF ENDOGENOUS P53 IN VARIOUS TUMOUR CELL LINES A, 
Representative examples of immunoblots for p53 (DO-1 antibody) following SDS-gradient native 
PAGE analysis at the indicated SDS concentrations (%) for four different tumour cell lines. B, 
Immunoblots for p53 (DO-1 antibody) following Proteinase K treatment at the indicated 
concentration (µg/ml) for 15 min at 37 °C of the soluble and the pellet fraction from various tumour 
cell lines endogenously expressing p53. C, Immunoblots for p53 (DO-1 antibody) following a sodium 
dodecyl sulfate (SDS) gradient extraction using the indicated SDS concentration (%) from various 
tumour cell lines endogenously expressing p53. S = Soluble fraction (diluted 1/20), P = Pellet 
fraction. On the right of the blots, we indicated the pseudo ∆∆G values.  
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved.
 FIGURE 3. TUMOUR ASSOCIATED STRESS INDUCES THE FORMATION OF 53-POSITIVE 
INCLUSION BODIES A, Quantification of high content screening showing boxplot analysis of the 
number of p53 positive nuclear inclusion bodies per cell in control conditions and upon MG132 
treatment (10µM) in the indicated tumour cell lines. B-E, Quantification of high content screening 
showing boxplot analysis of the number of p53- positive inclusions per cell in control conditions, and 
upon the application of various tumour-associated stress conditions, including 0.2% hypoxia, 1 or 
10µM MG132 proteotoxic stress, hypoglycemia (0% glucose in DMEM/10%FCS) or oxidative stress 
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by treatment with NiCl2 (100µM). F, Immunoblots for p53 (DO-1 antibody) following a sodium 
dodecyl sulfate (SDS) gradient extraction using the indicated SDS concentration (%) from various 
tumour cell lines endogenously expressing p53 upon MG132 treatment (10µM for 8h). S = Soluble 
fraction (diluted 1/20), P = Pellet fraction. On the right of the blots, we indicated the pseudo ∆∆G 
values. G, Parallel analysis of the HCT116 cell line upon exposure to various conditions (indicated 
below the panels) of (top) high content images for the presence of p53-nIBs and (bottom) mRNA 
expression of p53 target genes. * indicates statistical significance compared to the control condition. 
§ indicates statistical significance compared to the cisplatin-treated condition. 
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FIGURE 4. P53 INCLUSION BODIES ARE PML AND SIGMAR POSITIVE AND CONTAIN 
MISFOLDED P53 A-F, Immunofluorescence staining of the HACAT tumour cell line showing nuclei 
(A, DAPI, blue), p53 staining using the DO-1 antibody (B, red), PML-staining (C, green) and the 
overlay (D) and the quantification upon high content screening showing boxplot analysis of number 
of p53-PML double positive inclusions per cell (E) and the percentage over the total number of p53 
inclusions (F). Scale bars denote 10 µm in all panels. G, Immunoblots for p53 using DO-1 of HACAT 
cell lysates of control and MG132 treated cells as indicated. Left panel: total amount of p53 in the 
supernatant or pellet fraction upon lysis in the presence or absence of MG132. Right panel: 
immunoprecipitation of the supernatant fraction, shown in the left panel, using the indicated 
conformational p53 antibodies. H-S, Immunofluorescent staining of colon cancer biopsies of the 
primary tumour (H-O) and lymph nodes containing metastatic tumour cells (P-S), showing nuclei 
(H,L,P; DAPI, blue), p53 staining using the DO-1 antibody (I,M,Q; red), PML-staining (J,N,R; green) 
and the overlay (K,O,S). * indicates statistical significance compared to the parental cell line. 
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 FIGURE 5. AGGREGATED P53 ALTERS THE PROTEOSTATIC NETWORK  OF CANCER CELLS A, 
Boxplot representation of the fluorescence intensities measured by high content imaging in single 
cells of 8 tumour cell lines following p53 immunostaining using the DO-1 antibody (Ct = unmodified 
control cells; KO = knockout cells). B-F, Barplots describing the percentage difference between the 
knockout (KO) and parental/control (Ct) cells of the average intensities of the indicated marker 
proteins following immunostaining for HSF1 (B), HSC70 and HSP90 (C), BAG2 and DNAJB1 (D), 
HSP70 and HSPA6 (E) and HDAC6 and SQSTM1 (F). G, Expression of high levels of mutant p53 leads 
to stabilization of a reporter for the ubiquitin-proteasome system. HEK293 control and HEK293 cells 
stably expressing an unstable green fluorescent reporter for the ubiquitin-proteasome system 
(UbG76V-GFP) were transfected with p53-WT-mCherry (black squares), p53-R175H-mCherry (red 
circles) or p53-R273H-mCherry (green diamonds). After 72 hr, UbG76V-GFP levels were analyzed by 
flow cytometry. The relationship between p53 levels on the x axis and of normalised UbG76V-GFP on 
the y axis is plotted and shows a concentration-dependent accumulation of UbG76V-GFP in the 
presence of mutant p53. The data shown are from a single representative experiment out of three 
independent repeats. * indicates statistical significance compared to the parental cell line. NS, not 
significant.  
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FIGURE 6. SURVIVAL ANALYSIS OF COLON CANCER AND GLIOBLASTOMA PATIENTS A,B, 
Principle component analysis of the mRNA expression levels from various proteostatic proteins to 
determine a linear explanatory model. The coefficients for each protein of the model are indicated in 
(K), and the resulting differentiation between the subcategories is indicated in (L). C,D, Survival 
analysis for disease free (C) and overall (D) survival based on the immunofluorescent p53 staining of 
tissue sections from biopsies of the clinical cohort of colon cancer patients. NUCINC50 vs. SOLUB: 
DFS: Hazard Ratio = 3.3 [1.1-10.1], p=0.024*, median DFS: 44.4 vs. 59.6 months; OS: Hazard Ratio of 
4.6 [1.0-21.2], p=0.033*; median OS: 49.8 vs. 62.8 months; values indicate: mean [95% CI]. E,F, 
Survival analysis for disease free (E) and overall (F) survival based on the immunofluorescent p53 
staining of tissue sections from biopsies of Glioblastoma (GBM) patients. NUCINC50 vs. 
SOLUB+AGG1: DFS: Hazard Ratio = 2.1 [1.03-4.5], p=0.040*, median DFS: 12.5 vs. 5 months; OS: 
Hazard Ratio of 2.6 [1.2-5.9], p=0.020*; median OS: 21 vs. 10 months.  G,H, Survival analysis for 
overall survival based on immunofluorescent p53 staining (G) or p53 genotype (H), both of the 
subset of 92 biopsies of the clinical cohort of colon cancer patients that were subjected to deep 
sequencing. Statistics (G): NUCINC50 vs. SOLUB: OS: Hazard Ratio of 7.0 [0.85-95.3], p=0.025*, 
median 0S: 50.2 vs. 61.2 months and (H) Wild-type vs. mutant p53: OS: Hazard Ratio of 0.7 [0.2-2.2], 
p=0.545, median OS: 49.8 vs. 50.6 months. Values indicate: mean [95% CI] 
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Tables 
TABLE 1: QUANTIFICATION OF THE DIFFERENT AGGREGATION PHENOTYPES OBSERVED BY IMMUNOFLUORESCENCE IN COLON CANCER AND GLIOBLASTOMA 
  Colon cancer  Glioblastoma  
 Category n % n % 
Nuclear staining No p53 staining 34 20.9 15 25 
 Nuclear p53 staining 129 79.1 45 75 
 Total 163  60  
Nuclear inclusions No p53 staining 34 20.9 15 25 
 p53 staining, no nuc inclusions 38 23.3 17 28.3 
 p53 staining, <5% nuc inclusions 48 29.4 15 25 
 p53 staining, >50% nuc inclusions 43 26.4 13 21.7 
 Total 163  60  
Cytoplasmic staining No p53 staining 34 20.9 15 25 
 p53 staining, no cytoplasmic stain 92 56.4 39 65 
 p53 staining, <5% cytoplasmic stain 29 17.8 5 8.3 
 p53 staining, >50% cytoplasmic stain 8 4.9 1 1.7 
 Total 163  60  
Cytoplasmic inclusions No p53 staining 34 20.9 15 25 
 p53 staining, no cyto inclusions 125 76.7 43 71.6 
 p53 staining, <5% cyto inclusions 3 1.8 2 3.3 
 Nuclear p53 staining, >50% cyto 1 0.6 0 0 
 Total 163  60  
Cytoplasmic staining AND 
nuclear inclusions No 133 81.6 58 96.7 
 Yes 30 18.4 2 3.3 
 Total 163  60
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Table 2: Overview of the genetic and biochemical parameters of endogenous p53 in various tumour cell lines 
Cell line Tumour type p53 genotype 
Pseudo 
ΔΔG 
(FoldX) 
Total p53 
expression 
(MSD) 
Blue Native Page 0.5% SDS resistance? 
IP 
pAB1620
IP 
pAB240
Saos2 Osteosarcoma Null Null 0 Not detectable ND ND ND 
A549 Lung WT 0 1623 Not aggregating No 2 0 
HEK293 Human embryonic kidney WT 0 11507 Not aggregating No 2 1 
LnCAP Prostate WT 0 587 Not detectable ND 0 0 
HCT116 Colon WT 0 6398 Not aggregating No 2 0 
U2OS Osteosarcoma WT 0 863 Not aggregating No 1 0 
SBC5 Lung R248L 0.03 16504 Not aggregating No 2 0 
SW1783 Astrocytoma R273H 1.03 105286 Not aggregating No 2 1 
U251 Gliobastoma R273H 1.03 70207 Not aggregating No 2 1 
Widr Colon R273H 1.03 159257 Not aggregating No  2 2 
PLCPRF5 Liver R249S 1.03 4678 Not aggregating No 1 2 
HT1376 Bladder P250L 1.57 25372 Aggregating Partial 2 2 
C33A Retinoblastoma R273C 1.65 35906 Mildly aggregating No 2 2
SKNSH neuroblastoma R156P 3.53 79583 Aggregating Yes 0 2 
CHL1 Melanoma H193R 3.63 18972 Aggregating Yes 1 2 
Mel1617 Melanoma (skin) Y220C 4.15 8547 Aggregating Yes 0 2 
HCC827 Lung V218 >5 19608 Aggregating Yes 0 2
Ln405 Glioblastoma R282W >5 22826 Aggregating No 0 2
Hacat Immortalized skin R282W/H179Y >5 121295 Mildly aggregating Partial 2 2 
Du145 Prostate P223L/V274F >5 25054 Aggregating Yes 0 2 
Detroit 562 Pharynx R175H >5 79770 Aggregating Yes 0 2 
VMCUB Bladder StopY126/R175H >5 301 Not detectable ND ND ND
ND: not determined; 0: no signal; 1: low signal; 2: high signal; IP: immunoprecipitation; the pseudo ∆∆G (kCal/mole) is a measure for the 
destabilizing effect of the mutation as measured by the FoldX force field (the higher, the more destabilizing the mutation
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